Better Practice: Trimodality Treatment, 3x Improvement in Stage 3 Non Small Cell Lung Cancer (NSCLC)



Every year, there will be a certain treatment that will be the highlight of discussion and presentations in every oncology meetings/ events.

Last year, it was durvalumab, which delivered superior results for a subgroup of non-small cell lung cancer (NSCLC)

Addition of immunotherapy, durvalumab, to chemotherapy and radiotherapy treatment in stage 3 lung cancer prevent cancer from progressing for longer time.

Suitable patients must be:

  • Stage 3 lung cancer
  • Histology: non-small cell lung cancer (NSCLC) –  adenocarcinoma, squamous
  • Good performance status a.k.a able to walk about and perform daily activities independently
  • Complete chemotherapy and radiotherapy treatments
PACIFIC trial overview


  • On average, 3x longer duration without disease progression 16.8 months (trimodality) vs 5.6 months (chemotherapy and radiotherapy only).
  • At 18 months, no progression of cancer in 44% of patients on trimodality (vs 27% patients on chemotherapy and radiotherapy only).
PACIFIC trial: Progression free survival (PFS)

Important: This medication, which will likely cost above 100k, is currently available for free as it is awaiting registration and approval from regulatory authority.

The above result is undeniably good and I hope the final results (overall survival) will be as good as well. I hope more patients can benefit from this treatment when the price become more affordable (it’s not even launch yet in Malaysia!).

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s